PFS and OS in patients with r/r HL. (A) PFS in all treated patients (blue line) compared with the subset of patients who received per-protocol ASCT (without prior additional salvage; green line). Patients who started an antitumor therapy (excluding stem cell transplant or post-ASCT consolidative therapy) other than the study treatment prior to documentation of tumor progression were censored at the date of the most recent disease assessment prior to start of new therapy that was adequate to document progressive disease. (B) PFS in patients with relapse disease at study entry vs primary refractory patients. (C) OS in all treated patients.